Skip to main content

Vescica Ileale Padovana (VIP) / Padua Ileal Bladder (PIB)

The Vescica Ileale Padovana (VIP), also known as the Padua Ileal Bladder (PIB), is a detubularized double-folded orthotopic ileal neobladder first described by Filiberto Pagano and Walter Artibani at the University of Padova, Italy in 1989 (published 1990). It gained popularity due to its technical simplicity, favorable urodynamic properties, and adaptability to robotic intracorporeal construction, and has become one of the most commonly used neobladder configurations in the robotic era — particularly at the Regina Elena National Cancer Institute (Rome), which has the largest robotic intracorporeal PIB experience worldwide.[1][2][3]


Historical Development

YearMilestone
1989Pagano / Artibani / Ligato / Piazza / Garbeglio / Passerini described VIP at Padova[1]
1990Initial 16-pt series — 87% daytime / 81% nighttime continence; capacity 400–650 mL; pressure 17 cmH₂O[1]
2009Ferriero / Simone (Rome) — first detailed early/late urodynamic assessment (n=46, 48-mo FU)[4]
2010Novara / Artibani validated-questionnaire study (n=113, 44 mo) — landmark on outcome overestimation without patient-completed questionnaires[5]
2012–2014Simone (Rome) — totally intracorporeal robotic PIB, first 45 patients in Eur Urol[3]
2019Cacciamani (Padova) — robot-assisted VIP (ra-VIP) replicating open principles intracorporeally[2]
2023Tuderti (Rome) — largest long-term robotic PIB series (n=251, 5-yr outcomes)[6]
2024Tuderti — 10-year learning curve analysis (n=200) showing significant continence improvement over decade[7]

Design Principles

The VIP / PIB was designed for a near-spherical low-pressure high-capacity reservoir through detubularization + double-folding:[1][2]

  • Detubularization — antimesenteric opening disrupts coordinated peristalsis
  • Double folding — folds twice for spherical configuration; maximizes volume / minimizes pressure (Laplace)
  • Antireflux — original VIP incorporates an intact (non-detubularized) afferent ileal segment 8–10 cm behind the reservoir; indirect upper-tract protection without a formal valve
  • Technical simplicity — designed to be simpler / faster than Hautmann W or Kock pouch with comparable urodynamics

Surgical Technique

Open VIP (original Pagano / Artibani)[1][2]

  1. Bowel isolation — ~ 40–50 cm distal ileum, 15–20 cm proximal to ileocecal valve
  2. Bowel continuity — ileoileal anastomosis
  3. Afferent-limb identification — proximal 8–10 cm kept intact (non-detubularized)
  4. Detubularization — remaining segment opened along antimesenteric border
  5. Double-folding — wider, more spherical reservoir than single-fold U-shape
  6. Posterior plate — adjacent medial edges sutured into posterior wall
  7. Urethral anastomosis — most dependent point of reservoir → membranous urethra
  8. Ureteral reimplantation — both ureters to proximal afferent limb (Bricker or Wallace)
  9. Anterior closure — fold free edges upward, suture together

Robot-Assisted VIP (ra-VIP, Cacciamani 2019)[2]

Faithfully replicates open-VIP principles intracorporeally:

  • Median operative time 390 min (IQR 284–470); EBL 300 mL; no conversions
  • Median LOS 17 d
  • 90-d major complications 40% (n = 6)
  • Daytime continence at 12 mo 62%; 93% alive at 17-mo mean FU

Robotic Intracorporeal PIB — Simone / Rome (2012–present)[3][6][7]

Largest and most mature robotic PIB experience using a partly-stapled intracorporeal technique:

  • Median operative time 305 min (IQR 282–345)
  • Median EBL 210 mL; median LOS 9 d
  • No intraoperative transfusions or conversions

Functional Outcomes

Original open VIP (Pagano 1990, n = 16)[1]

ParameterResult
Daytime continence87% (14/16)
Nighttime continence81% (13/16; dry sleep 6–7 hr)
Capacity400–650 mL
Mean pressure at capacity17 cmH₂O
Pressure wavesNone in 50%; 30–50 cmH₂O wide waves with 250 mL threshold in 50%
RefluxAbsent
Voiding mechanismAbdominal straining + perineal relaxation

Validated questionnaire study (Novara / Artibani 2010, n = 113)[5]

The first validated-questionnaire VIP assessment (AUA-SI, ICIQ-UI SF, IIEF-5) — landmark demonstrating physician-reported outcomes significantly overestimate function:

ParameterResult
Median FU44 mo
CIC requirement13% (16/113)
Median AUA-SI9 (IQR 4.5–16)
LUTS severity (mild / moderate / severe)48.5% / 40.2% / 11.3%
Median ICIQ-UI SF6 (IQR 3–10)
Fully continent (no leakage at all)17.7%
Slight / moderate / severe incontinence31.9% / 35.4% / 15%
No pad or safety pad — daytime~ 90%
No pad or safety pad — nighttime~ 80%
Potency (IIEF-5 ≥ 17)~ 20%

Predictors: ASA class (OR 9.0, p = 0.03) and BMI (OR 1.5, p = 0.023) predicted CIC need; age was the only predictor of LUTS severity.

Urodynamic assessment (Ferriero / Simone 2009, n = 46, 12 → 48 mo)[4]

Parameter12 mo48 mop
Cystometric capacityStableStableNS
End-filling pressureHigherSignificantly lower0.0005
Peak flow pressureHigherSignificantly lower0.0007
Post-void residualHigherSignificantly lower0.013
Involuntary contractionsFewerSignificantly increased0.0012
Contraction amplitudeComparable0.084
Daytime continence96%90%
Nighttime continence60%

Conclusion: despite detubularization, ileal tone is maintained and likely prevents excessive enlargement. End-filling and peak-flow pressure improve over time; involuntary contractions increase but without increasing amplitude.

Robotic intracorporeal PIB long-term

SeriesnFUDaytimeNighttimeNotes
Simone 2018 (initial 45)452 yr73.3%55.5%First robotic PIB; 2-yr DFS 72.5%, CSS 82.3%
Tuderti 2023 (long-term)251 (192 ION)5 yr78.6% (1-yr)48.3% (1-yr)5-yr DFS 66.5%, CSS 65.4%, OS 61.5%; Trifecta 64.1%
Tuderti 2024 (10-yr LC)20010 yrAAPC 11.45% improving trendAAPC 10.05% improving trendLC is independent predictor of continence
Presicce 2021 (late complications)210 (80% PIB)30 moUEA stenosis 14%; eGFR ↓ ≥ 20% in ~ 50%; UTI 37%

Comparative outcomes

Parekh 2000 multi-institutional 100-pt comparison (W-shape, ileal+afferent, Padua, right colon, sigmoid): no substantial differences among methods provided sphincter preservation and low-pressure principles maintained.[9]


Complications

Early — robotic PIB Simone series[3][6]

  • Perioperative complications 44.4% (initial 45)
  • 30-d complications 57.8% overall (17.8% Clavien ≥ III)
  • 180-d complications 77.8% overall (35.5% severe)
  • Both decreased significantly with the learning curve (30-d p = 0.04)[7]

Late — Presicce 2021 robotic PIB (n=210)[8]

ComplicationIncidence
Ureteroileal anastomotic stenosis14%
eGFR decrease ≥ 20%~ 50%
UTI (especially first 12 mo)37%
Incisional hernia20%
Lymphocele10%
Bowel occlusion2%
Metabolic acidosis (systemic)1%

The 14% ureteroileal stenosis is notably higher than 2.7–6% in large open Studer / Hautmann series — may reflect learning curve and different anastomotic techniques.

Predictors[6][7]

  • Age (HR 0.98, p = 0.03), female sex (HR 0.57, p = 0.008), and Clavien ≥ 3 complications (HR 0.55, p = 0.03) — independent predictors of daytime incontinence
  • Learning curve is an independent predictor of both daytime (HR 1.008, p < 0.05) and nighttime continence

Metabolic & Bone Health

Giannini 1997 dedicated VIP-patient bone-metabolism study (n = 25):[10]

  • Mild metabolic acidosis (lower plasma HCO₃⁻)
  • Decreased bone mineral density at femoral neck and Ward's triangle
  • Lifelong alkali supplementation and bone-density monitoring warranted

For pharmacologic management see Vitamin B12 supplementation, Urinary acidifiers & alkalinizers, and Mucus management.


VIP / PIB in Women

Tuderti 2020 sex-sparing robotic PIB (n=11):[11]

  • Median operative time 255 min; LOS 7 d
  • Low-grade complications 36.3%; no high-grade complications
  • No new-onset CKD stage 3b
  • Daytime continence at 1 yr 90.9%; nighttime 86.4%
  • 72.7% sexually active at 12 mo
  • QoL, physical / emotional functioning improved significantly (p ≤ 0.04)
  • Urinary symptoms and sexual function worsened at 3 mo but significantly recovered at 1 yr

These results are notably better than historical female neobladder series, likely reflecting the sex-sparing approach (preserved uterus, vaginal wall, NVBs) and careful patient selection.


VIP vs FloRIN

The Florence Robotic Intracorporeal Neobladder (FloRIN) vs open VIP at the same institution (Di Maida 2022):[12][13]

ParameterFloRIN (robotic)VIP (open)p
Daytime continence75.4%ComparableNS
Pad-free (daytime)40.6%
Nighttime continence65.2%ComparableNS
Neobladder complianceHigherLower0.03
Urgency QoLBetter0.01
Psychological QoLBetter0.02
Physical self-acceptanceBetter0.02

FloRIN showed comparable functional outcomes with higher compliance and better QoL in several domains. Anceschi 2022 head-to-head urodynamic / functional comparison of robotic PIB vs FloRIN confirmed comparable mid-term outcomes.[14]


VIP vs Studer

Zhu 2025 propensity-matched comparison of ileum-valve-pouch (IVP, based on VIP principles) vs modified Studer pouch (n = 127; 84 matched):[15]

  • No significant differences in operative time, urinary-diversion time, CSS, or OS
  • Lower UTI rehospitalization rate in the VIP group (p = 0.039)
  • At 12 mo, VIP group had lower rates of eGFR decrease (p = 0.031) and less renal-function damage (p < 0.05)

Learning Curve

Tuderti 2024 10-yr learning-curve analysis (n=200):[7]

  • Hospital stay decreased significantly over time (p = 0.002)
  • 30-d complications decreased significantly (p = 0.04)
  • Trifecta (negative margins + no high-grade complications + no readmission) significantly improved (p < 0.05)

VIP in Context — Comparison Table

FeatureVIP / PIBStuderHautmann (W)FloRIN
Year introduced1989198519862016
Ileal length~ 40–50 cm~ 54–60 cm~ 60–70 cm~ 50 cm
ConfigurationDouble-foldU-fold + afferent limbW-fold (quadruple)Asymmetric U + L-fold
Afferent limbYes (8–10 cm intact)Yes (20 cm isoperistaltic)None (original); chimney optionalNo
Capacity400–650 mL450–500 mL413–550 mL240 mL (early)
Pressure at capacity17 cmH₂O~ 20 cmH₂O26–30 cmH₂OLow
Daytime continence (open)87–96%87–93%90–96%
Daytime continence (robotic)62–78.6%90%75.4%
Nighttime continence60–81%72–79%82–95%65.2%
CIC rate13%7–10%4–13%
Largest robotic series251 patients (Rome)40 patients100 patients (Florence)

Key Takeaways

  1. The VIP / PIB is a technically simple double-folded detubularized ileal neobladder with excellent urodynamics — very low pressure (17 cmH₂O) and high capacity (400–650 mL)
  2. It has become the dominant neobladder technique in the robotic intracorporeal era, with the largest single-center robotic series (Rome, n = 251)[6]
  3. Novara 2010 validated-questionnaire study was a landmark — only 17.7% fully continent (no leakage at all), though ~ 90% used no pad or only a safety pad during the day — patient-completed instruments significantly change reported outcomes[5]
  4. Urodynamics improve over time — end-filling and peak-flow pressure decrease significantly from 12 to 48 mo while capacity remains stable[4]
  5. Learning curve is a critical determinant — continence improved significantly over a 10-yr period (AAPC 11.45% daytime / 10.05% nighttime)[7]
  6. Metabolic consequences include mild chronic acidosis with measurable decreased BMD at femoral neck and Ward's triangle — long-term alkali and bone-density monitoring warranted[10]

Strengths and Limitations

Strengths

  • Technical simplicity (designed faster than Hautmann W or Kock)
  • Excellent urodynamic properties (capacity 400–650 mL, pressure 17 cmH₂O, no reflux in original series)
  • Favorable urodynamic evolution over time (Ferriero 2009)
  • Largest robotic intracorporeal neobladder experience worldwide
  • Adaptable to robotic construction (both Padova ra-VIP and Rome PIB)
  • Potential renal-function advantage over Studer at 12 mo
  • Excellent results in women with sex-sparing approach (90.9% daytime, 86.4% nighttime)

Limitations

  • Higher ureteroileal-stenosis rate in robotic series (14%) vs open Studer / Hautmann (2.7–6%)
  • eGFR decrease ≥ 20% in ~ 50% in late-complication analysis
  • Validated-questionnaire data show only 17.7% fully continent
  • Nighttime continence remains a challenge (48–81% depending on series)
  • Learning curve significantly impacts outcomes — early-experience patients have worse continence and more complications
  • Limited long-term data compared to Hautmann (35 yr) and Studer (20 yr)

See Also


References

1. Pagano F, Artibani W, Ligato P, et al. "Vescica ileale Padovana: a technique for total bladder replacement." Eur Urol. 1990;17(2):149–154. doi:10.1159/000464024

2. Cacciamani GE, De Marco V, Sebben M, et al. "Robot-assisted vescica ileale Padovana: a new technique for intracorporeal bladder replacement reproducing open surgical principles." Eur Urol. 2019;76(3):381–390. doi:10.1016/j.eururo.2018.11.037

3. Simone G, Papalia R, Misuraca L, et al. "Robotic intracorporeal Padua ileal bladder: surgical technique, perioperative, oncologic and functional outcomes." Eur Urol. 2018;73(6):934–940. doi:10.1016/j.eururo.2016.10.018

4. Ferriero M, Simone G, Rocchegiani A, et al. "Early and late urodynamic assessment of Padua ileal bladder." Urology. 2009;73(6):1357–1362. doi:10.1016/j.urology.2009.01.053

5. Novara G, Ficarra V, Minja A, De Marco V, Artibani W. "Functional results following vescica ileale Padovana (VIP) neobladder: midterm follow-up analysis with validated questionnaires." Eur Urol. 2010;57(6):1045–1051. doi:10.1016/j.eururo.2010.01.007

6. Tuderti G, Mastroianni R, Chiacchio G, et al. "Long-term oncologic and functional outcomes following robot-assisted radical cystectomy and intracorporeal Padua ileal bladder: results from a single high-volume center." World J Urol. 2023;41(9):2359–2366. doi:10.1007/s00345-023-04523-8

7. Tuderti G, Mastroianni R, Anceschi U, et al. "Learning curve for intracorporeal robotic Padua ileal bladder: 10-year functional assessment from a high-volume single-centre series." BJU Int. 2024;134(1):103–109. doi:10.1111/bju.16328

8. Presicce F, Leonardo C, Tuderti G, et al. "Late complications of robot-assisted radical cystectomy with totally intracorporeal urinary diversion." World J Urol. 2021;39(6):1903–1909. doi:10.1007/s00345-020-03378-7

9. Parekh DJ, Gilbert WB, Smith JA. "Functional lower urinary tract voiding outcomes after cystectomy and orthotopic neobladder." J Urol. 2000;163(1):56–58.

10. Giannini S, Nobile M, Sartori L, et al. "Bone density and skeletal metabolism in patients with orthotopic ileal neobladder." J Am Soc Nephrol. 1997;8(10):1553–1559. doi:10.1681/ASN.V8101553

11. Tuderti G, Mastroianni R, Flammia S, et al. "Sex-sparing robot-assisted radical cystectomy with intracorporeal Padua ileal neobladder in female: surgical technique, perioperative, oncologic and functional outcomes." J Clin Med. 2020;9(2):E577. doi:10.3390/jcm9020577

12. Di Maida F, Grosso AA, Tasso G, et al. "Robot-assisted radical cystectomy with Florence robotic intracorporeal neobladder (FloRIN): functional and urodynamic features compared with a contemporary series of open vescica ileale Padovana (VIP)." Eur J Surg Oncol. 2022;48(8):1854–1861. doi:10.1016/j.ejso.2022.04.007

13. Minervini A, Vanacore D, Vittori G, et al. "Florence robotic intracorporeal neobladder (FloRIN): a new reconfiguration strategy developed following the IDEAL guidelines." BJU Int. 2018;121(2):313–317. doi:10.1111/bju.14077

14. Anceschi U, Di Maida F, Flammia RS, et al. "Robotic intracorporeal Padua ileal neobladder vs FloRIN pouch: comparison of mid-term urodynamic and functional profiles." Minerva Urol Nephrol. 2022;74(6):825–827. doi:10.23736/S2724-6051.22.04884-4

15. Zhu Z, Zhu Y, Ying W, et al. "Comparison of the anti-reflux ileum valve-pouch orthotopic neobladder and the Studer technique after radical cystectomy: surgical and renal functional outcomes." World J Surg Oncol. 2025;23(1):359. doi:10.1186/s12957-025-03699-0